iTeos Belgium SA
- Country
- 🇧🇪Belgium
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors
- Conditions
- Selected Advanced Solid Tumors
- Interventions
- Drug: EOS006215Drug: Anticancer agent
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- iTeos Belgium SA
- Target Recruit Count
- 94
- Registration Number
- NCT06877533
- Locations
- 🇺🇸
Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States
🇺🇸Florida Cancer Specialists (FSC SAC DDU) Sarasota, Sarasota, Florida, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
- Conditions
- Locally Advanced NSCLC - Non-Small Cell Lung CancerMetastatic NSCLC - Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- iTeos Belgium SA
- Target Recruit Count
- 186
- Registration Number
- NCT05403385
- Locations
- 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸Innovative Clinical Research Institute (ICRI), Whittier, California, United States
🇺🇸Mid-Florida Hematology & Oncology Centers, PA, Orange City, Florida, United States
Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- iTeos Belgium SA
- Target Recruit Count
- 16
- Registration Number
- NCT05289492
- Locations
- 🇺🇸
Banner MD Anderson, Gilbert, Arizona, United States
🇺🇸Eastern Connecticut Hematology & Oncology, Norwich, Connecticut, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
- Conditions
- Head and Neck CancerAdvanced CancerLung CancerMelanoma
- Interventions
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- iTeos Belgium SA
- Target Recruit Count
- 153
- Registration Number
- NCT05060432
- Locations
- 🇺🇸
University of California San Diego, San Diego, California, United States
🇺🇸Hackensack University Medical Center, Bergen, New Jersey, United States
🇧🇪GZA Ziekenhuizen campus Sint-Augustinus, Antwerpen, Antwerp, Belgium
First-In-Human Study of EOS884448 in Participants With Advanced Cancers.
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2022-06-16
- Lead Sponsor
- iTeos Belgium SA
- Target Recruit Count
- 40
- Registration Number
- NCT04335253
- Locations
- 🇧🇪
GZA Ziekenhuizen campus Sint-Augustinus, Antwerp, Belgium
🇧🇪Institut Jules Bordet, Brussels, Belgium
🇧🇪Cliniques universitaires St Luc-UCL, Brussels, Belgium